New Clinical Trials Regulation published
Recommendation
5-7 November 2024
Hamburg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
The new Clinical Trials Regulation with the official title "Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC" has been published in the Official Journal of the EU.
Besides the goal to simplify clinical trial approvals, the Regulation aims to foster transparency on the conduct of trials in the European Economic Area (EEA). This will be achieved now by providing the legal basis for the publication of clinical trial results. The respective IT-tools and platforms will be implemented by the European Medicines Agency (EMA) to "support sponsors and experts in the Member States in carrying out their roles in relation to the authorisation of trials, their supervision, safety reporting and compliance activities, as well as to enable public access to information on clinical trials".
Source: EMA press release
Related GMP News
05.09.2024Clinical Trials Regulation - Version 6.9 of the Q&As
23.07.2024Pilot Results on Regulatory-Led RWE Generation
23.07.2024ICH M12 Guideline on Drug Interaction Studies
20.06.2024Draft ICH M14 Guideline on Real-World Data for Safety Assessment
20.06.2024Glossary of Terms and Definitions for Innovative Clinical Trials
21.05.2024Real-World Evidence: FDA´s Considerations for Non-Interventional Studies